Novartis CEO: Inclisiran Could Be Largest Medicine In NHS History
Pact To Make As-Yet-Unapproved Drug Widely Available
Executive Summary
The Swiss major has been enthusing about its population-based agreement in the UK for the investigational gene silencing cholesterol lower and plans for similar schemes in other countries.
You may also be interested in...
Novartis Bounces Back From COVID-19 And Cosentyx Keeps Climbing
Sales at the Swiss major have returned to around 80%-90% of their pre-pandemic levels, according to CFO Harry Kirsch after unveiling a healthy set of second-quarter financials.
Long Wait Ahead For Novartis's Leqvio In US
The timeline for a US resubmission of the closely watched PCSK9-targeting cholesterol treatment could be either Q2 or Q3 and approval will depend on whether the FDA needs to make a physical inspection of an Italian facility.
The Top Five (Non-COVID) Pharma Stories Of 2020
The (virtual) doors closing on the J.P. Morgan Healthcare Conference is the sign for the biopharma industry that the new year has truly started, but before we get too far into 2021, Scrip has taken a look at five of the biggest non-COVID-19 story themes of 2020 in no particular order.